Popular drugs like Ozemic and Monjauro aid in managing diabetes by lowering blood sugar levels. They have surged in popularity because they hasten weight loss. And this new class of drugs —GLP-1 ...

Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

U.S. stock futures point lower as investors evaluate disappointing tech earnings, shares of Alphabet drop as the Google parent's cloud revenue falls short of estimates, and Advanced Micro Devices ...

Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, one of Europe's largest listed companies, advanced nearly 3% in Denmark. Dig ...

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Novo Nordisk A/S expects sales to surge again this year as the Danish drugmaker builds supply for blockbuster diabetes ...

Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely ...

A gold-standard University College of London study found a type of weight-loss jab had no benefit in alleviating a condition ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...

Christina Aguilera has lost her famous curves – and weight loss drug Ozempic is to blame, with the pop superstar now barely ...